LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People

benzinga.com/news/fda/25/08/46796085/lenz-therapeutics-eye-drop-scores-first-fda-approval-for-age-related-blurred-vision-condition-impacting-

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only FDA-approved aceclidine-based eye drop for presbyopia in adults.
Presbyopia is an age-related…

This story appeared on benzinga.com, 2025-08-01 14:25:51.
The Entire Business World on a Single Page. Free to Use →